TY - JOUR
T1 - Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia
T2 - 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning
AU - Ishigooka, Jun
AU - Nakagome, Kazuyuki
AU - Ohmori, Tetsuro
AU - Iwata, Nakao
AU - Inada, Ken
AU - Iga, Jun Ichi
AU - Kishi, Taro
AU - Fujita, Kiyoshi
AU - Kikuchi, Yuka
AU - Shichijo, Toshiaki
AU - Tabuse, Hideaki
AU - Koretsune, Shotatsu
AU - Terada, Hiroshi
AU - Terada, Haruko
AU - Kishimoto, Toshifumi
AU - Tsutsumi, Yuichiro
AU - Ohi, Kazutaka
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Background: We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medication Program for Schizophrenia (JUMPs), a 104-week naturalistic study. Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 104-week study. Patients aged ≥ 20 years with schizophrenia requiring antipsychotic treatment or a switch from previous therapy were enrolled. The primary endpoint was treatment discontinuation rate over 104 weeks. Secondary endpoints included remission rate, Personal and Social Performance (PSP), safety, Positive and Negative Syndrome Scale (PANSS), and quality of life (QOL; EuroQol-5 dimension). Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). Treatment discontinuation rates (aripiprazole, 80.5%; blonanserin, 81.2%; paliperidone, 71.4%) were not significantly different (p = 0.2385) among the treatment groups at 104 weeks; comparable outcomes were observed for endpoints, including remission (42.9%, 46.7%, and 45.8%), PANSS, and safety. In the overall cohort, while the improvement in the PSP total score at Week 104 was not significantly different from baseline, a significant improvement (p < 0.05) in QOL and total PANSS scores (including all subscales) was observed at Week 104 compared with baseline. Multivariable analysis identified a shorter disease duration and a higher chlorpromazine-equivalent antipsychotic dosage level (≥ 1000 mg) before switching to monotherapy as predictors of treatment discontinuation. Conclusions: The 104-week treatment outcomes were comparable between groups; the overall trend of improvement in remission rate, safety, and QOL suggests the importance of continued treatment. Clinical trial registration: UMIN-Clinical Trials Registry UMIN000007942 (public release date: 14/05/2012).
AB - Background: We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medication Program for Schizophrenia (JUMPs), a 104-week naturalistic study. Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 104-week study. Patients aged ≥ 20 years with schizophrenia requiring antipsychotic treatment or a switch from previous therapy were enrolled. The primary endpoint was treatment discontinuation rate over 104 weeks. Secondary endpoints included remission rate, Personal and Social Performance (PSP), safety, Positive and Negative Syndrome Scale (PANSS), and quality of life (QOL; EuroQol-5 dimension). Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). Treatment discontinuation rates (aripiprazole, 80.5%; blonanserin, 81.2%; paliperidone, 71.4%) were not significantly different (p = 0.2385) among the treatment groups at 104 weeks; comparable outcomes were observed for endpoints, including remission (42.9%, 46.7%, and 45.8%), PANSS, and safety. In the overall cohort, while the improvement in the PSP total score at Week 104 was not significantly different from baseline, a significant improvement (p < 0.05) in QOL and total PANSS scores (including all subscales) was observed at Week 104 compared with baseline. Multivariable analysis identified a shorter disease duration and a higher chlorpromazine-equivalent antipsychotic dosage level (≥ 1000 mg) before switching to monotherapy as predictors of treatment discontinuation. Conclusions: The 104-week treatment outcomes were comparable between groups; the overall trend of improvement in remission rate, safety, and QOL suggests the importance of continued treatment. Clinical trial registration: UMIN-Clinical Trials Registry UMIN000007942 (public release date: 14/05/2012).
KW - 104-week effectiveness
KW - Discontinuation rate
KW - Monotherapy
KW - Real-world outcomes
KW - Remission rate
KW - Second-generation antipsychotics
UR - http://www.scopus.com/inward/record.url?scp=85203265018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85203265018&partnerID=8YFLogxK
U2 - 10.1186/s12888-024-06031-4
DO - 10.1186/s12888-024-06031-4
M3 - Article
C2 - 39237918
AN - SCOPUS:85203265018
SN - 1471-244X
VL - 24
JO - BMC Psychiatry
JF - BMC Psychiatry
IS - 1
M1 - 600
ER -
